Navigation Links
Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
Date:1/4/2008

FRAZER, Pa., Jan. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Frank Baldino, Jr., Ph.D., Chairman and CEO will present at the JP Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA. Dr. Baldino will deliver a one hour presentation on Tuesday, January 8, 2008 beginning at 2:00 p.m. Pacific Time (11 a.m. Eastern Time).

Live Web Cast and Archived Replay

Members of the financial and investment community, the media and other interested parties can access a live web cast of the presentation through the investor relations section of the company's website http://www.cephalon.com. Following the live presentation, a replay of the presentation will be available for two weeks on the company's website.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous produc
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
5. DaVita Inc. to Present at JPMorgan Healthcare Conference
6. Hologic to Present at the 26th Annual JP Morgan Healthcare Conference
7. WebMD to Present at Upcoming Investor Conferences
8. Neurochem to present at JPMorgan Healthcare Conference
9. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
10. MedCath Corporation to Present at the 26th Annual JPMorgan Healthcare Conference
11. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , Ad in Today,s Washington Post ...ewswire-USNewswire/ -- If the Catholic bishops ...tative measures we take for granted may be under t...ght to bear on the debate over healthcare reform h...Washington Post warns of the likely impact if tha...
(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire/ -- The...Italy) in conjunction with a team of doctors from ...a six-year long research study confirming that Pec...ted Linoleic Acid), an Omega-6 polyunsaturated fat...d which shows bioactive properties for humans. ,...
(Date:12/2/2009)..., , DALLAS, Dec. 2 Proving...the parts," Texas Health Harris Methodist Hospital...rine Corps Reserves Toys for Tots program to make ... families. The organizations are combining their ... and other non-perishable food items, culminating ...
(Date:12/2/2009)... Study finds myriad microbes in tobacco, but risk ...Day News) -- New research provides evidence that ...uding bacteria that cause respiratory disease. ,...ed out, the authors of the new study aren,t sure w...o bacteria is nothing new: Microbes surround us ev...
(Date:12/2/2009)..., BOSTON Alcoholic beverages popular among youth...th high youth readership than alcoholic drinks con...ately high youth exposure to such targeted alcohol... the Boston University School of Public Health, Jo... Virtual Media Resources who conducted the study -...
Breaking Medicine News(10 mins):Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:New Study Confirms Health Benefits of Pecorino Romano Cheese 2Health News:New Study Confirms Health Benefits of Pecorino Romano Cheese 3Health News:Texas Health Harris Methodist Hospital Southlake Joins With U.S. Marine Corps Reserves Toys for Tots to Spread Holiday Cheer 2Health News:Smokers Inhaling Germs With Each Cigarette 2Health News:Alcohol companies target youths with magazine ads, new study shows 2
... pill that could give a longer lease of life to pa... when given along with chemotherapy drugs. Pa... Novacea lived for an average of an extra nine mon...f the vitamin without running the risk of side eff...
...cial transplantation—including the psychological a...e—a Working Party of the Royal College of Surgeons... in performing further face transplants, according...tation should not be attempted until further resea...
...vard School of Public Health (HSPH) finds that pol... in a net savings of over $180 billion, even witho...ated with avoided fear and suffering. This first s...of Risk Analysis. The history of polio vaccin...
... and gamblers in Britain. A study reveals// that E...inos then on vegetables and fruits. On an ave...ambling in United Kingdom. Online gambling has als...enagers getting addicted to this habit. An analysi...
...eans high pressure in the arteries. High blood pre...iller’ because one can have it for years without k...P when his blood pressure reading is around 120/80... Approx. 2.5 million Canadians have high-norm...
...e of the largest eye care hospital networks in sou...ith seven more in the offing. The Chennai fa...emraj, a prominent ophthalmic surgeon and managing...t for the eight hospitals. Fifty percent of the fu...
Other Medicine News:Health News:Royal College Issues Revised Guidelines for Face Transplantation 2Health News:Royal College Issues Revised Guidelines for Face Transplantation 3Health News:Billions of Dollars Saved in U.S. By Polio Vaccination 2Health News:Slightly High Blood Pressure is Also Hazardous 2
(Date:12/1/2009)...., Dec. 1 Merck & Co., Inc. to...ration (FDA) has approved ZEGERID OTC(TM) (omepraz...r over-the-counter treatment of frequent heartburn...y Schering-Plough HealthCare Products, Inc., the c...c. Schering-Plough and Merck merged on November 3,...
(Date:12/1/2009)... Reportlinker.com announces that a ...alogue: ,, Latin American Pharmaceutical Mark...lysis, forecasts and growth opportunities ,, ...can-Pharmaceutical-Market-Outlook-To-2014-Policy-e...portunities.html ,, The $28.8bn Latin Americ...
(Date:12/1/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, The Future of Oncology Therapeutics -...g, Product Pipeline and Deals Analysis ,, htt...cology-Therapeutics---Market-Forecasts-to-2015-Com...nalysis.html ,, Summary ,, The author has...
Breaking Medicine Technology:FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 2FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 3FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 4Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 2Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 3Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 4Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 5Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 6Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 7Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 8Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3New Anti Clotting Drug Beats Plavix 55655 1New Anti Clotting Drug Beats Plavix 55655 2New Anti Clotting Drug Beats Plavix 55655 3New Anti Clotting Drug Beats Plavix 55655 4Video 3A Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Pa 55651 1Video 3A Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Pa 55651 2Video 3A Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Pa 55651 3Video 3A Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Pa 55651 4Video 3A Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Pa 55651 5Video 3A Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Pa 55651 6Get Ready for Ragweed 55647 1Get Ready for Ragweed 55647 2
... MATEO, Calif., Sept. 4 BioForm Medical,Inc. (Nas...ical study of,Polidocanol, conducted in Germany by...SLER & Co. GmbH (Kreussler), successfully met the ...DA as part of a New Drug Application,(NDA) process...(Efficacy and safety of,Aethoxysklerol compared to...
...otal Study Seeks to Enroll 750 Women at More Than ... QuatRx Pharmaceuticals, a,privately-held biopharm...rcialization of compounds to treat endocrine, meta...d that it has initiated a second,Phase 3 clinical ...any,s,estrogen-free oral therapy in development fo...
Other Medicine Technology:338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products: